Impacts
Societal impact
Patient’s health
More precise and cost-efficient diagnosis and treatment of HT
Patients’ blood pressure will be controlled much more efficiently and quickly, thereby ameliorating or maintaining their health.
Improved patient adherence to treatment
The MOMICS strategy will allow prescribing the right treatment to each patient, avoiding repeated treatment failures that are often accompanied by side effects and improving patient’s adherence to treatment.
Reduction of health care disparity over the territory
Work on translational, ethical and regulatory issues will provide strategies for the widespread implementation of MOMICS tests outside of specialized referral centers.
Improved therapeutic outcomes
Better targeted therapies and earlier disease intervention will improve cure rate, reduce complications (cardiovascular, metabolic, psychiatric) and increase QoL.
Patient quality of life
Improved quality of life through improved treatment response and reduction of cardiovascular complications.
Scientific impact
Public and private sector
Scientific knowledge
Improved understanding of the pathophysiological mechanisms involved in HT, allowing the redefinition of a novel, prognostically and therapeutically relevant disease taxonomy for the most common cardiovascular risk factor, and thereby providing major benefits for patient care.
New tools for rapid clinical readout and availability of personalized medicine
Design of appropriate clinical trials according to current recommendations for the validation of MOMICS biomarkers may have widespread applicability to other clinical situations, providing new tools that ensure rapid clinical readout and availability of personalized medicine to patients.
Ethical, legal and regulatory framework for AI-based technology in health system
Research on those matters will support the new web-based tools development for the implementation of MOMICS based diagnostics in clinical practice.
Economic Knowledge
Economic evaluation will provide knowledge on the use of omics on patient care pathways, outcomes and costs with widespread applications for implementation of omics into stratified approaches to be beneficially applied by both the public and private sectors for health promotion and disease prevention.
Economic impact
Healthcare system
A Decrease in healthcare costs
Reduced costs of unnecessary drug therapy and/or treatment of side effects, and costs associated to complications and reduced QoL and ensure appropriate patient monitoring through personalized medicine. Establishment of new guidelines will allow implementation of earlier, more precise and cost-efficient diagnosis and treatment, with widespread availability of diagnostic tests outside of specialized referral centers.
Improved cost-effectiveness metrics
MOMICS biomarkers will enable more effective treatment for hypertensive patients in daily clinical setting, with a potential major impact on number of disability adjusted life years associated to HT.
Wider impacts
_
Technological innovation in personalized medicine approach
This personalized medicine approach to hypertensive patients will positively impact on their QoL and healthy life years and prevent HT-mediated organ damage and cardiovascular events such as stroke, heart failure, myocardial infarction; in turn, this will reduce health costs and the burden of HT as a disease.
Secure decision making thanks to IA
HT-ADVANCE includes research on ethical, legal, and regulatory issues from the innovative activities implemented in this project that concern AI and Machine Learning, which will lead to a set of recommendations in this field. These will contribute to the future ethical use and implementation of such AI systems in the health sector and facilitate public acceptance and trust.